Cannabotech medical cannabis products reduce pain by more than 80%

Estimated reading time: 3 minutes

Products formulated using cannabis and mushroom extracts, are said to have been shown to reduce pain sensation by 80 – 100 per cent.

Biomedical company, Cannabotech, says its unique formulation of fungal extracts and cannabinoids have been shown in studies to achieve an 80 – 100 per cent reduction in pain sensation.

The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC.

The animal study of inflammatory pain, examined the efficacy of IntegrativePain products designed to reduce pain, including that emanating from an inflammatory source like arthritis, back pain or chemotherapy side-effects.

The results showed that adding defined concentrations of other cannabinoids, such as THCV and CBG allowed the researchers to use lower concentrations of THC to achieve very high medical efficacy.

They also showed a significant decrease in pain intensity independent of a direct decrease in inflammation, suggesting that the products immediately affect pain mechanisms on top of their anti-inflammatory activity.

The fungal composition, made up of seven extracts from different mushrooms, achieved very high efficacy by itself, as did the cannabinoids. But as expected, the fungal and cannabinoid combined achieved a stronger effect than each individually. 

This result reinforces Cannabotech’s claim that treating the endocannabinoid system, using cannabinoids, jointly with other systems, like the immune system, using mushrooms, achieves a more potent medical effect than each of these components individually.

Dr Isaac Angel, Cannabotech’s pharmacological consultant, said: “Pain is one of the central problems the healthcare industry has been attempting to solve for decades. Most pain patients’ aches emanate from a combined, partly inflammatory source, which significantly impairs their quality of life.

“Cannabotech’s products have shown heightened efficiency in the current mouse model. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products. We will continue to work to provide a cure for patients.”

IntegrativePain products are part of Cannabotech’s Integrative Oncology product series designed to treat cancer patients and those experiencing chemotherapy’s side-effects. 

The experiment also emphasised the importance of tailoring treatment, with Cannabotech developing three pain-treatment formulas: one for pain from an inflammatory source; another for pain from a neuropathic origin; and a third for pain from integrated sources. 

The treatment is expected to launch in the UK, alongside Israel and the US, in the second half of 2022.

Currently, around 50- 80 per cent of cancer patients receive additional integrative treatment alongside chemotherapy (mainly herbal products, including cannabis). 

The key reasons for using integrative products include strengthening the immune system, improving treatment efficacy and reducing adverse events.

Cannabotech, CEO, Elhanan Shaked, added: “This is a significant milestone in Cannabotech’s growth to becoming a leader in integrative oncology medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment in several cancers, and form part of  the Company’s goal to define a new standard for the medical cannabis industry.

“Pain is the leading indication amongst medical cannabis users. However, while most products on the market are inflorescences-based cannabis with high THC concentrations, Cannabotech presents a different, oil-based concept rich in other active ingredients, whose unique composition shows outstanding results without the unwanted side effects.”